Beta-mimetic drugs and possible prevention of respiratory distress syndrome

Br J Obstet Gynaecol. 1975 Apr;82(4):285-8. doi: 10.1111/j.1471-0528.1975.tb00635.x.

Abstract

The prophylactic value of beta-mimetic drugs in preventing respiratory distress syndrome (RDS) is investigated by comparing 29 preterm infants of ritodrine treated mothers with 34 preterm infants of a control group. Five cases of RDS (17 per cent) occurred among the infants of treated mothers as compared with 12 cases (35 per cent) in the control group (p = 0-09). The difference is, however, statistically significant for the group of infants weighing less than 2300 grams (p = 0-01) which includes all infants affected with RDS.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adrenergic beta-Agonists / therapeutic use*
  • Apgar Score
  • Birth Weight
  • Clinical Trials as Topic
  • Female
  • Gestational Age
  • Humans
  • Infant, Newborn
  • Male
  • Pregnancy
  • Propanolamines / therapeutic use*
  • Respiratory Distress Syndrome, Newborn / prevention & control*
  • Retrospective Studies
  • Ritodrine / therapeutic use*

Substances

  • Adrenergic beta-Agonists
  • Propanolamines
  • Ritodrine